Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016

Monzr M. Al Malki, Richard Jones, Qing Ma, Dean Lee, Yair Reisner, Jeffrey S. Miller, Peter Lang, Suradej Hongeng, Parameswaran Hari, Samuel Strober, Jianhua Yu, Richard Maziarz, Domenico Mavilio, Denis Claude Roy, Chiara Bonini, Richard E. Champlin, Ephraim J. Fuchs, Stefan O. Ciurea

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34+ cell selection, "megadoses" of purified CD34+ cells, or selective depletion of T cells) or newer platforms of in vivo depletion of T cells, with either post-transplantation high-dose cyclophosphamide or intensified immune suppression, have contributed to better outcomes, with survival similar to that in HLA-matched donor transplantation. Further efforts are underway to control viral reactivation using modified T cells, improve immunologic reconstitution, and decrease the relapse rate post-transplantation using donor-derived cellular therapy products, such as genetically modified donor lymphocytes and natural killer cells. Improvements in treatment-related mortality have allowed the extension of haploidentical donor transplants to patients with hemoglobinopathies, such as thalassemia and sickle cell disease, and the possible development of platforms for immunotherapy in solid tumors. Moreover, combining HSCT from a related donor with solid organ transplantation could allow early tapering of immunosuppression in recipients of solid organ transplants and hopefully prevent organ rejection in this setting. This symposium summarizes some of the most important recent advances in HaploSCT and provides a glimpse in the future of fast growing field.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Stem Cell Transplantation
Tissue Donors
T-Lymphocytes
Transplantation
Hematopoietic Stem Cell Transplantation
Hemoglobinopathies
Thalassemia
Sickle Cell Anemia
Organ Transplantation
Natural Killer Cells
Immunotherapy
Cyclophosphamide
Immunosuppression
Lymphocytes
Transplants
Recurrence
Survival
Mortality
Therapeutics
Neoplasms

Keywords

  • Cellular therapy
  • Haploidentical transplantation
  • Immunologic reconstitution
  • Post-transplantation cyclophosphamide
  • T cell depletion

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. / Al Malki, Monzr M.; Jones, Richard; Ma, Qing; Lee, Dean; Reisner, Yair; Miller, Jeffrey S.; Lang, Peter; Hongeng, Suradej; Hari, Parameswaran; Strober, Samuel; Yu, Jianhua; Maziarz, Richard; Mavilio, Domenico; Roy, Denis Claude; Bonini, Chiara; Champlin, Richard E.; Fuchs, Ephraim J.; Ciurea, Stefan O.

In: Biology of Blood and Marrow Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

Al Malki, MM, Jones, R, Ma, Q, Lee, D, Reisner, Y, Miller, JS, Lang, P, Hongeng, S, Hari, P, Strober, S, Yu, J, Maziarz, R, Mavilio, D, Roy, DC, Bonini, C, Champlin, RE, Fuchs, EJ & Ciurea, SO 2018, 'Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2018.01.008
Al Malki, Monzr M. ; Jones, Richard ; Ma, Qing ; Lee, Dean ; Reisner, Yair ; Miller, Jeffrey S. ; Lang, Peter ; Hongeng, Suradej ; Hari, Parameswaran ; Strober, Samuel ; Yu, Jianhua ; Maziarz, Richard ; Mavilio, Domenico ; Roy, Denis Claude ; Bonini, Chiara ; Champlin, Richard E. ; Fuchs, Ephraim J. ; Ciurea, Stefan O. / Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. In: Biology of Blood and Marrow Transplantation. 2018.
@article{f556d0a3258540a4a73021e2cc9c3728,
title = "Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016",
abstract = "The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34+ cell selection, {"}megadoses{"} of purified CD34+ cells, or selective depletion of T cells) or newer platforms of in vivo depletion of T cells, with either post-transplantation high-dose cyclophosphamide or intensified immune suppression, have contributed to better outcomes, with survival similar to that in HLA-matched donor transplantation. Further efforts are underway to control viral reactivation using modified T cells, improve immunologic reconstitution, and decrease the relapse rate post-transplantation using donor-derived cellular therapy products, such as genetically modified donor lymphocytes and natural killer cells. Improvements in treatment-related mortality have allowed the extension of haploidentical donor transplants to patients with hemoglobinopathies, such as thalassemia and sickle cell disease, and the possible development of platforms for immunotherapy in solid tumors. Moreover, combining HSCT from a related donor with solid organ transplantation could allow early tapering of immunosuppression in recipients of solid organ transplants and hopefully prevent organ rejection in this setting. This symposium summarizes some of the most important recent advances in HaploSCT and provides a glimpse in the future of fast growing field.",
keywords = "Cellular therapy, Haploidentical transplantation, Immunologic reconstitution, Post-transplantation cyclophosphamide, T cell depletion",
author = "{Al Malki}, {Monzr M.} and Richard Jones and Qing Ma and Dean Lee and Yair Reisner and Miller, {Jeffrey S.} and Peter Lang and Suradej Hongeng and Parameswaran Hari and Samuel Strober and Jianhua Yu and Richard Maziarz and Domenico Mavilio and Roy, {Denis Claude} and Chiara Bonini and Champlin, {Richard E.} and Fuchs, {Ephraim J.} and Ciurea, {Stefan O.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2018.01.008",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016

AU - Al Malki, Monzr M.

AU - Jones, Richard

AU - Ma, Qing

AU - Lee, Dean

AU - Reisner, Yair

AU - Miller, Jeffrey S.

AU - Lang, Peter

AU - Hongeng, Suradej

AU - Hari, Parameswaran

AU - Strober, Samuel

AU - Yu, Jianhua

AU - Maziarz, Richard

AU - Mavilio, Domenico

AU - Roy, Denis Claude

AU - Bonini, Chiara

AU - Champlin, Richard E.

AU - Fuchs, Ephraim J.

AU - Ciurea, Stefan O.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34+ cell selection, "megadoses" of purified CD34+ cells, or selective depletion of T cells) or newer platforms of in vivo depletion of T cells, with either post-transplantation high-dose cyclophosphamide or intensified immune suppression, have contributed to better outcomes, with survival similar to that in HLA-matched donor transplantation. Further efforts are underway to control viral reactivation using modified T cells, improve immunologic reconstitution, and decrease the relapse rate post-transplantation using donor-derived cellular therapy products, such as genetically modified donor lymphocytes and natural killer cells. Improvements in treatment-related mortality have allowed the extension of haploidentical donor transplants to patients with hemoglobinopathies, such as thalassemia and sickle cell disease, and the possible development of platforms for immunotherapy in solid tumors. Moreover, combining HSCT from a related donor with solid organ transplantation could allow early tapering of immunosuppression in recipients of solid organ transplants and hopefully prevent organ rejection in this setting. This symposium summarizes some of the most important recent advances in HaploSCT and provides a glimpse in the future of fast growing field.

AB - The resurgence of haploidentical stem cell transplantation (HaploSCT) over the last decade is one of the most important advances in the field of hematopoietic stem cell transplantation (HSCT). The modified platforms of T cell depletion either ex vivo (CD34+ cell selection, "megadoses" of purified CD34+ cells, or selective depletion of T cells) or newer platforms of in vivo depletion of T cells, with either post-transplantation high-dose cyclophosphamide or intensified immune suppression, have contributed to better outcomes, with survival similar to that in HLA-matched donor transplantation. Further efforts are underway to control viral reactivation using modified T cells, improve immunologic reconstitution, and decrease the relapse rate post-transplantation using donor-derived cellular therapy products, such as genetically modified donor lymphocytes and natural killer cells. Improvements in treatment-related mortality have allowed the extension of haploidentical donor transplants to patients with hemoglobinopathies, such as thalassemia and sickle cell disease, and the possible development of platforms for immunotherapy in solid tumors. Moreover, combining HSCT from a related donor with solid organ transplantation could allow early tapering of immunosuppression in recipients of solid organ transplants and hopefully prevent organ rejection in this setting. This symposium summarizes some of the most important recent advances in HaploSCT and provides a glimpse in the future of fast growing field.

KW - Cellular therapy

KW - Haploidentical transplantation

KW - Immunologic reconstitution

KW - Post-transplantation cyclophosphamide

KW - T cell depletion

UR - http://www.scopus.com/inward/record.url?scp=85041640816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041640816&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.01.008

DO - 10.1016/j.bbmt.2018.01.008

M3 - Article

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -